Related Experiment Video
Updated: May 15, 2026
Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy
Published on: March 10, 2023
The surgical management of neuroendocrine tumour hepatic metastases
1Royal United Hospital Bath NHS Trust, Combe Park, Bath BA1 3NG, United Kingdom.
Abstract:
Although rare in incidence, patients with neuroendocrine tumours (NET) live for many years and so have a high prevalence, and NETs frequently metastasise to the liver (NLM). Numerous treatment options have been implemented both for cure, and to implement disease control. Surgical treatment consists of curative resection, palliative cytoreductive resection and transplantation. Complete surgical resection is possible only in a subset of people with NLMs due to various factors. Ablative therapies may also be used, either as an adjunct to surgery or as a primary treatment. The purpose of the article is to summarise surgical treatment strategies in the management of patients with hepatic neuroendocrine metastases.
Insights
Neuroendocrine tumors (NETs) often spread to the liver. This review summarizes surgical strategies for managing these hepatic neuroendocrine metastases (NLMs), focusing on resection and ablative therapies.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Neuroendocrine Tumor Management
Background:
- Neuroendocrine tumors (NETs) are rare but have a high prevalence due to long patient survival.
- Hepatic neuroendocrine metastases (NLMs) are common, necessitating effective management strategies.
- Current treatments aim for cure or disease control, with surgery being a key modality.
Purpose of the Study:
- To provide a comprehensive summary of surgical treatment strategies for hepatic neuroendocrine metastases (NLMs).
- To review the role of various surgical interventions, including resection and ablative therapies, in managing NLMs.
- To highlight factors influencing the feasibility of complete surgical resection.
Main Methods:
- Literature review of surgical management options for hepatic neuroendocrine metastases.
- Analysis of different surgical approaches: curative resection, palliative cytoreductive resection, and transplantation.
- Evaluation of ablative therapies as adjuncts or primary treatments.
Main Results:
- Complete surgical resection of NLMs is achievable in a subset of patients.
- Surgical options range from curative resection to palliative cytoreductive surgery and liver transplantation.
- Ablative therapies offer alternative or complementary treatment modalities.
Conclusions:
- Surgical management is crucial for patients with hepatic neuroendocrine metastases.
- Treatment strategies must be individualized based on resectability and patient factors.
- A combination of surgical resection and ablative therapies can optimize outcomes for NLMs.
